Abstract:Background: Tacrolimus (TAC) and mycophenolic acid (MPA) are commonly used immunosuppressive therapies after renal transplant. Our objective was to quantify TAC and MPA concentrations in peripheral blood mononuclear cells (PBMCs) using liquid chromatography tandem mass spectrometry (LC-MS/MS) and to evaluate and validate the performance of the methodology. A prospective follow-up cohort study was conducted to determine whether intracellular concentrations were associated with adverse outcomes in renal transplants. Methods: PBMCs were prepared using the Ficoll separation technique and purified with erythrocyte lysis. The cells were counted using Sysmex XN-3100 and then packaged and frozen according to a 50 μL volume containing 1.0 × 106 cells. TAC and MPA were extracted using MagnaBeads and quantified using an LC-MS/MS platform. The chromatography was run on a reversed-phase Waters Acquity UPLC BEH C18 column (1.7 μm, 50 mm × 2.1 mm) for gradient elution separation with a total run time of 4.5 min and a flow rate of 0.3 mL/min. Mobile phases A and B were water and methanol, respectively, each containing 2 mM ammonium acetate and 0.1% formic acid. Renal transplant recipients receiving TAC and MPA in combination were selected for clinical validation and divided into two groups: a stable group and an adverse outcome group. The concentrations were dynamically monitored at 5, 7, 14, and 21 days (D5, D7, D14, and D21) and 1, 2, 3, and 6 months (M1, M2, M3, and M6) after operation. Results: Method performance validation was performed according to Food and Drug Administration guidelines, showing high specificity and sensitivity. The TAC and MPA calibration curves were linear (r2 = 0.9988 and r2 = 0.9990, respectively). Both intra-day and inter-day imprecision and inaccuracy were less than 15%. Matrix effects and recoveries were satisfactory. The TAC and MPA concentrations in 304 "real" PBMC samples from 47 renal transplant recipients were within the calibration curve range (0.12 to 16.40 ng/mL and 0.20 to 4.72 ng/mL, respectively). There was a weak correlation between PBMC-C0TAC and WB-C0TAC (p < 0.05), but no correlation was found for MPA. The level of immunosuppressive intra-patient variation (IPV) was higher in PBMC at 77.47% (55.06, 97.76%) than in WB at 34.61% (21.90, 49.85%). During the dynamic change in C0TAC, PBMC-C0TAC was in a fluctuating state, and no stable period was found. PBMC-C0TAC did not show a significant difference between the stable and adverse outcome group, but the level of the adverse outcome group was generally higher than that of the stable group. Conclusions: Compared with conventional therapeutic drug monitoring, the proposed rapid and sensitive method can provide more clinically reliable information on drug concentration at an active site, which has the potential to be applied to the clinical monitoring of intracellular immunosuppressive concentration in organ transplantation. However, the application of PBMC-C0TAC in adverse outcomes of renal transplant should be studied further.

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Pharmacokinetics of Mycophenolic Acid in Chinese Kidney Transplant Patients

Short-Term Intensified Dosage Regimen of Mycophenolic Acid is Associated with Less Acute Rejection in Kidney Transplantation from Donation after Circulatory Death.

Limited Sampling Strategy for Mycophenolic Acid in Chinese Kidney Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus During the Early Posttransplantation Phase

Tacrolimus and cyclosporine A combined with mycophenolate mofetil influence on the plasma mycophenolic acid concentration

Evaluation of the Area under the Curve of Enteric-Coated Mycophenolate Sodium Using a Limited Sampling Strategy in Chinese Kidney Transplant Recipients .

Pharmacokinetics Study of Mycophenolate Mofetil in Renal Transplantation Patients

245.5: Efficacy and Safety of an Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in De Novo Kidney Transplant Recipients in China: A Prospective Cohort Study

Mycophenolate Sodium Enteric-Coated Tablets Versus Mycophenolate Mofetil for Inhibition of Bone Marrow in Renal Transplant Repicients

Estimation of Mycophenolic Acid Area under the Curve with Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

Effects Of Mycophenolate Mofetil Combined With Corticosteroids For Induction Therapy Of Microscopic Polyangiitis

Pharmacokinetics, Efficacy, and Safety of Mycophenolate Mofetil in Combination with Standard-Dose or Reduced-Dose Tacrolimus in Liver Transplant Recipients

Proton pump inhibitors on concentration of different preparations of mycophenolic acid in kidney transplantation recipients

Application of Mycophenolate Mofetil Combined with Low-Dose Tacrolimus and Corticosteroid Regimen after Renal Transplantation

Dynamic Monitoring of Intracellular Tacrolimus and Mycophenolic Acid Therapy in Renal Transplant Recipients Using Magnetic Bead Extraction Combined with LC-MS/MS

The Evaluation of Enteric-Coated Mycophenolate Sodium in Cardiac Deceased Donor Liver Transplant Patients in China

Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients

Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients

A Study on Monitoring of MPA Plasm Concentration of Chinese Kidney Transplantation Recipients

Short‐term Therapeutic Drug Monitoring of Mycophenolic Acid Reduces Infection: a Prospective, Single‐center Cohort Study in Chinese Living‐related Kidney Transplantation